Abstract | OBJECTIVE: MATERIAL AND METHODS: This study included patients with a metastatic NEC of digestive or unknown primary site. All patients received platinum- etoposide as first-line chemotherapy. Primary endpoint was progression-free survival (PFS). Secondary endpoints were clinical/morphological responses, toxicity, and overall survival (OS). RESULTS: Twenty-seven patients were included: 17 received dacarbazine and 10 temozolomide as post-first line treatments. Median PFS was 3.0 (95%CI (2.2;3.7)) months. There was no significant difference between dacarbazine and temozolomide on PFS. Clinical and morphological responses were found in 12 and 9 patients, respectively. Median OS was 7.2 (95%CI (2.2;12.2)) months. The toxicity profile was that expected with such treatments. CONCLUSION:
|
Authors | Thomas Couronne, Paul Girot, Julien Hadoux, Thierry Lecomte, Alice Durand, Caroline Fine, Katia Vandevoorde, Catherine Lombard-Bohas, Thomas Walter |
Journal | Endocrine connections
(Endocr Connect)
Vol. 9
Issue 6
Pg. 498-505
(Jun 2020)
ISSN: 2049-3614 [Print] England |
PMID | 32380470
(Publication Type: Journal Article)
|